Author Archives: zymecom

← Older posts

Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension

Posted on by zymecom

Cambridge, UK, 20 May 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

TTP plc collaborates with Quotient Ltd to transform transfusion diagnostics and beyond

Posted on by zymecom

TTP enables development of MosaiQ™ diagnostic platform for transfusion typing and disease screening Cambridge, UK, 20 May 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today that it has partnered with Quotient Ltd (NASDAQ:QTNT), … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge

Posted on by zymecom

Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer Cambridge, UK, 20th May 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Mologic achieves breakthrough in ultra-sensitive point-of-care diagnostics and develops new platform technology

Posted on by zymecom

Visually-read device delivers up to 1,000-fold improvement in sensitivity to support surveillance and elimination efforts of global epidemics  Since 2016, the Bill & Melinda Gates Foundation has committed $9.7 million to establish and accelerate the CARD technology programme Bedfordshire, UK, … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Mologic achieves breakthrough in ultra-sensitive point-of-care diagnostics and develops new platform technology

US Patent Office Grants Charpentier/Doudna Key CRISPR Patent

Posted on by zymecom

US patent number 10,266,850 was previously involved in an interference proceeding  DUBLIN, Ireland, 23 April 2019: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced today that … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on US Patent Office Grants Charpentier/Doudna Key CRISPR Patent

TC BioPharm initiates Phase I trial of allogeneic gamma delta T cell therapy in Acute Myeloid Leukemia patients

Posted on by zymecom

Study to provide safety data on allogeneic use of GDTs prior to subsequent use of CAR-modified variants Glasgow, UK, 24 April 2019: TC BioPharm (TCB), a developer of allogeneic CAR-T immuno-oncology products, and leaders in Gamma Delta T (GDT) cell … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on TC BioPharm initiates Phase I trial of allogeneic gamma delta T cell therapy in Acute Myeloid Leukemia patients

Start Codon founded in Cambridge, UK, to deliver premier life science and healthcare business acceleration program

Posted on by zymecom

Start Codon, located in the heart of the Cambridge Cluster, aims to provide a much-needed world-class life science accelerator that offers significant funding and support to rapidly translate the most disruptive and innovative research into successful start-up companies. Start Codon’s … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Start Codon founded in Cambridge, UK, to deliver premier life science and healthcare business acceleration program

Bio-Rad Introduces Isotype-Specific Secondary Antibodies

Posted on by zymecom

HERCULES, Calif.–April 09, 2019–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Bio-Rad Introduces Isotype-Specific Secondary Antibodies

Metrion Biosciences appoints Dr Andrew Southan as Chief Executive Officer

Posted on by zymecom

Cambridge, UK, 08 April 2019:  Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on Metrion Biosciences appoints Dr Andrew Southan as Chief Executive Officer

European Patent Office Grants 3rd Charpentier/Doudna Patent Covering Uses of CRISPR/Cas9 in Human and Animals Cells

Posted on by zymecom

EPO Patent No. 3,401,400 issued to Dr. Emmanuelle Charpentier, University of California and University of Vienna  DUBLIN, Ireland, 03 April 2019: ERS Genomics Limited announced today that the European Patent Office (EPO) has issued a new patent to Dr. Emmanuelle Charpentier, … Continue reading

Posted in News from Zyme and the companies we work with | Comments Off on European Patent Office Grants 3rd Charpentier/Doudna Patent Covering Uses of CRISPR/Cas9 in Human and Animals Cells ← Older posts
  • People

    An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.

  • Keep in touch

    +44(0) 1223 968 920

    info@zymecommunications.com


     

  • Upcoming Events

    Zyme Communications will be providing support for its clients attending the following events:

    TIDES Oligonucleotide and Peptide Therapeutics

    When: Mon May 20 09:00 - Thu May 23 18:00
    Where: San Diego, USA

    ELRIG Advances in Cell Based Screening

    When: Wed May 22 09:00 - Fri May 24 18:00
    Where: Gothenburg, Sweden